Table 12Studies of atherosclerotic progression that reported coronary heart disease outcomes

Author or study acronym StatinPre-specified clinical event or spontaneous reportaSignificant reduction in clinical event or trend towards statin
LCAS
Fluvastatin147		Spontaneous reportTrend
ACAPS
Lovastatin148		Secondary endpointReduction in major cardiovascular events
CCAIT
Lovastatin149		Spontaneous reportTrend
MARS
Lovastatin150		Spontaneous reportTrend
REGRESS
Pravastatin155		Pre-specifiedReduction in percutaneous transluminal coronary angioplasty
PLAC-I
Pravastatin151		Pre-specifiedReduction in myocardial infarction
PLAC-II
Pravastatin152		Pre-specifiedReduction in combined: nonfatal myocardial infarction and death
KAPS
Pravastatin153		Spontaneous reportTrend
Sato, et al
Pravastatin154		Pre-specifiedReduction in overall death
MAAS
Simvastatin156		Spontaneous reportTrend
CIS
Simvastatin157		Spontaneous reportTrend
SCAT
Simvastatin158		Pre-specifiedReduction in revascularization
a

“Spontaneous report” means that the outcome was not a pre-specified endpoint for the study but was reported anyway.

From: Adults

Cover of Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5 [Internet].
Smith MEB, Lee NJ, Haney E, et al.
Portland (OR): Oregon Health & Science University; 2009 Nov.
Copyright © 2009, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.